BREAST CANCER

Postmenopausal patients with PIK3CA-mutant, hormone receptor–positive, HER2-negative advanced breast cancer in the SOLAR-1 trial experienced prolonged overall survival with alpelisib and fulvestrant even though the study did not cross the prespecified O’Brien-Fleming efficacy boundary (P ≤ .0161), according to research presented at the 2020 ESMO Virtual Congress.

The combination of atezolizumab, carboplatin, and nab-paclitaxel increased pathological complete response by 10% or more in “immune-rich” patients with high-risk and locally advanced triple-negative breast cancer, as well as turned PD-L1 negative tumors positive most patients treated with immunotherapy, according to the phase 3 NeoTRIPaPDL1 trial data presented at the 2020 ESMO Virtual Congress.

An improvement in progression-free survival and objective response rate was not observed with the addition of ipatasertib to paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive, HER2-negative advanced breast cancer.

Experts in breast oncology review 3 clinical cases of HER2+ breast cancer and discuss individualized treatment approaches for each patient.

The combination of atezolizumab and paclitaxel was not effective for the treatment of patients with treatment-naïve inoperable locally advanced or metastatic triple-negative breast cancer, according to an FDA alert.

The FDA granted a Priority Review to the New Drug Application for oral paclitaxel with encequidar for the treatment of patients with metastatic breast cancer.